Chemomab Therapeutics Ltd ADR (NASDAQ: CMMB) has experienced a rise in its stock price by 8.65 compared to its previous closing price of 1.04. However, the company has seen a fall of -2.59% in its stock price over the last five trading days. benzinga.com reported 2025-03-27 that Chemomab Therapeutics Ltd. CMMB on Thursday released results from the Open Label Extension (OLE) portion of the Phase 2 Spring trial assessing nebokitug for primary sclerosing cholangitis (PSC).
Is It Worth Investing in Chemomab Therapeutics Ltd ADR (NASDAQ: CMMB) Right Now?
CMMB has 36-month beta value of 0.59. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CMMB is 16.57M, and currently, short sellers hold a 1.63% ratio of that float. The average trading volume of CMMB on April 03, 2025 was 370.28K shares.
CMMB’s Market Performance
The stock of Chemomab Therapeutics Ltd ADR (CMMB) has seen a -2.59% decrease in the past week, with a -13.08% drop in the past month, and a -44.06% fall in the past quarter. The volatility ratio for the week is 18.02%, and the volatility levels for the past 30 days are at 12.06% for CMMB. The simple moving average for the past 20 days is -11.58% for CMMB’s stock, with a -26.58% simple moving average for the past 200 days.
Analysts’ Opinion of CMMB
Many brokerage firms have already submitted their reports for CMMB stocks, with Maxim Group repeating the rating for CMMB by listing it as a “Buy.” The predicted price for CMMB in the upcoming period, according to Maxim Group is $4 based on the research report published on May 13, 2024 of the previous year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see CMMB reach a price target of $6. The rating they have provided for CMMB stocks is “Outperform” according to the report published on May 06th, 2024.
ROTH MKM gave a rating of “Buy” to CMMB, setting the target price at $7 in the report published on December 19th of the previous year.
CMMB Trading at -31.15% from the 50-Day Moving Average
After a stumble in the market that brought CMMB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.69% of loss for the given period.
Volatility was left at 12.06%, however, over the last 30 days, the volatility rate increased by 18.02%, as shares sank -19.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -46.19% lower at present.
During the last 5 trading sessions, CMMB fell by -2.59%, which changed the moving average for the period of 200-days by -1.74% in comparison to the 20-day moving average, which settled at $1.2780. In addition, Chemomab Therapeutics Ltd ADR saw -37.57% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CMMB starting from OrbiMed Israel Partners Limite, who proposed sale 500,000 shares at the price of $2.03 back on Sep 12 ’24. After this action, OrbiMed Israel Partners Limite now owns shares of Chemomab Therapeutics Ltd ADR, valued at $1,015,000 using the latest closing price.
Stock Fundamentals for CMMB
The total capital return value is set at -1.08. Equity return is now at value -91.76, with -71.63 for asset returns.
The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -7406.77.
Currently, EBITDA for the company is 14672.0 with net debt to EBITDA at 0.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.98.
Conclusion
To put it simply, Chemomab Therapeutics Ltd ADR (CMMB) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
